You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR XARACOLL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for XARACOLL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02232178 ↗ Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant Completed Premier Research Group plc Phase 2 2014-10-20 Assess the pharmacokinetic profile of 2 doses of the XaraColl® implant after open laparotomy hernioplasty and assess the relative bioavailability of Xaracoll compared to a local bupivacaine infiltration.
NCT02232178 ↗ Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant Completed Innocoll Phase 2 2014-10-20 Assess the pharmacokinetic profile of 2 doses of the XaraColl® implant after open laparotomy hernioplasty and assess the relative bioavailability of Xaracoll compared to a local bupivacaine infiltration.
NCT02523599 ↗ Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty Completed Innocoll Phase 3 2015-08-01 This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled efficacy and safety study of postoperative pain in adults who are scheduled for unilateral inguinal hernioplasty via open laparotomy (tension-free technique). Patients will assess their postoperative pain intensity (PI) using an 11-point numerical rating scale (NRS) from 0 hour through 72 hours postoperatively. The expected maximum study duration for each patient will be up to 60 days, including a maximum 30-day screening period, the day of surgery and implantation, and a 30-day post implantation period including treatment and follow-up.
NCT02525133 ↗ Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty Completed Innocoll Phase 3 2015-09-05 This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled efficacy and safety study of postoperative pain in adults who are scheduled for unilateral inguinal hernioplasty via open laparotomy (tension-free technique). Patients will assess their postoperative pain intensity (PI) using an 11-point numerical rating scale (NRS) from 0 hour through 72 hours postoperatively. The expected maximum study duration for each patient will be up to 60 days, including a maximum 30-day screening period, the day of surgery and implantation, and a 30-day post implantation period including treatment and follow-up.
NCT03262688 ↗ Safety, Tolerability, PK, and Analgesic Effect of INL-001 in Children Following Open Inguinal Hernia Repair Recruiting Cmed Phase 3 2017-06-16 A multicenter, single-dose study in children 12 to <17 years of age, 6 to <12 years of age, and 2 to <6 years of age who are scheduled for elective open inguinal hernia repair. Enrollment in this study will start with the oldest age group (12 to <17 years) and will continue in a stepwise fashion until appropriate doses are established for all 3 pediatric age groups (12 to <17 years, 6 to <12 years, 2 to <6 years).
NCT03262688 ↗ Safety, Tolerability, PK, and Analgesic Effect of INL-001 in Children Following Open Inguinal Hernia Repair Recruiting Premier Research Group plc Phase 3 2017-06-16 A multicenter, single-dose study in children 12 to <17 years of age, 6 to <12 years of age, and 2 to <6 years of age who are scheduled for elective open inguinal hernia repair. Enrollment in this study will start with the oldest age group (12 to <17 years) and will continue in a stepwise fashion until appropriate doses are established for all 3 pediatric age groups (12 to <17 years, 6 to <12 years, 2 to <6 years).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for XARACOLL

Condition Name

Condition Name for XARACOLL
Intervention Trials
Pain, Postoperative 2
Hernioplasty 1
Inguinal Hernia 1
Postoperative Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for XARACOLL
Intervention Trials
Pain, Postoperative 3
Hernia, Umbilical 1
Hernia, Inguinal 1
Hernia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for XARACOLL

Trials by Country

Trials by Country for XARACOLL
Location Trials
United States 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for XARACOLL
Location Trials
Texas 4
California 3
Alabama 3
Florida 3
Utah 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for XARACOLL

Clinical Trial Phase

Clinical Trial Phase for XARACOLL
Clinical Trial Phase Trials
Phase 3 3
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for XARACOLL
Clinical Trial Phase Trials
Completed 3
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for XARACOLL

Sponsor Name

Sponsor Name for XARACOLL
Sponsor Trials
Innocoll 4
Premier Research Group plc 2
Cmed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for XARACOLL
Sponsor Trials
Industry 6
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.